PORTLAND, Oregon, March 12, 2015 /PRNewswire/ --
Erythropoietin is a glycoprotein hormone synthesized in the bone marrow that controls and regulates the mechanism of erythropoiesis (production of red blood cells). These erythropoietin (EPO) drugs are used for treatment of chemotherapy-induced anemia; anemia is a common side-effect occurring due to chemotherapy of End Stage Renal Diseases (ESRD), cancer and HIV. Improved recombinant DNA technology has led to development of synthetic forms of erythropoietin such as epoetin alfa, epoetin beta, darbepoetin alfa, epoetin omega, and epoetin delta among the others. The global EPO drugs market is thus driven by increasing number of patients suffering from anemic condition induced due to cancer, HIV and ESRD treatment; favorable reimbursements and increasing commercialization of EPO biosimilars. The global EPO drugs market would reach $11.9 billion by 2020, registering CAGR of 9.7% during 2014-2020.
Amongst all synthetic erythropoietin products, Epoetin alfa and its advance version, Darbepoetin alfa, are the most popular drugs. Epoetin alfa and Darbepoetin alfa collectively accounted for ~80% of total EPO drugs market revenue. Amgen Inc. was first company to innovate Epoetin alfa and Darbepoetin alfa that are branded/patented as Epogen and Aranesp respectively. However, expiration of Amgen's patent for Epogen has aided manufacturers of biosimilars to enter the EPO drugs market. Availability of numerous biosimilars has rendered low-cost option to the patients, therefore increased adoption rates for EPO drugs particularly in the developing regions.
Based on the applications, the global EPO drugs market is segmented into anemia associated with End Stage Renal Diseases (ESRD), cancer chemotherapy and, antiretroviral treatment (ART). Current research is focused toward expanding the applications of EPO drugs in other disease conditions such as neural diseases and wound healing.
Global EPO drugs market is segmented based on geography into North America, Europe, Asia Pacific and LAMEA. Europe is the leading geographical market owing to favorable reimbursement policies and less stringent and speedy regulatory approvals for EPO drugs.
Key companies profiled in the report are, Amgen Inc., Johnson & Johnson, Hospira Inc., Roche, LG Life Sciences Ltd., Biocon, Intas Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Ranbaxy Laboratories Ltd., and Celltrion, Inc.
- An in-depth analysis of current research and clinical developments within EPO drugs market is provided with key market dynamic factors that helps in understanding the behavior of market
- The report provides the quantitative analysis of the current market and estimations through 2013-2020 that assists in identifying the prevailing market opportunities to capitalize on
- Extensive analysis of the market is conducted by closely following key product positioning and monitoring the top contenders within the market framework
- Comprehensive analysis of all geographic regions are provided that helps in determining the prevailing opportunities in these geographies
- Key market players within the EPO drugs market are profiled in the report and their strategies are analyzed thoroughly, which helps in understanding competitive outlook of global EPO drugs market
Enquire about this report:http://www.bigmarketresearch.com/report-enquiry/22668
The global EPO drugs market is segmented based on products, applications and geography.
Market By Product Types
Market by Applications
- Anemia (Cancer and HIV treatment)
- Kidney Disorders (ESRD and Dialysis)
- Others (Neural Disease and Wound healing)
Market by Geography
- North America
For Download Sample:http://www.bigmarketresearch.com/request-sample/22668
Table Of Content:
Chapter 1 Introduction
Chapter 2 Executive Summary
Chapter 3 Market Overview
Chapter 4 Global Erythropoietin Market By Products
Chapter 5 Global Erythropoietin Market By Applications
Chapter 6 Global Erythropoietin Market By Geography
Chapter 7 Company Profiles
Browse Similar Reports:
Global Telemedicine Market: Telemedicine overcomes the barrier of distance by providing clinical health care through information technology and telecommunication.
It makes health service more accessible, particularly in isolated rural areas where medical care is not consistently available primarily due to the location. Telemedicine enables effective communication between medical staff and patients, and facilitates the transmission of crucial health and medical information. Telemedicine plays a vital role in saving human lives, especially in emergencies and critical situations.
To Get Details:http://www.bigmarketresearch.com/telemedicine-market
Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market: Acute Lymphocytic/Lymphoblastic leukemia is a kind of blood or bone marrow cancer.
It occurs in lymphocytes which are white blood cells. It can then easily spread to the other parts of the body such as liver, spleen, lymph nodes and others. The number of cases of these diseases is rising at an alarming rate all over the globe. The rising incidence of acute Lymphoblastic/ Lymphocytic leukemia and innovative therapies related to it are the major drivers for this market.
With the arsenal of different search reports, we help you here to look and buy research reports that will be helpful to you and your organization. Our research reports have the capability and authenticity to support your organization for growth and consistency.
With the window of opportunity getting open and shut at a speed of light, it has become very important to survive in the market and only the fittest and competent enough can do so. So, we try and provide with latest changes in the market that can suit your needs and help you take decision accordingly.
5933 NE Win Sivers Drive,
#205, Portland, OR 97220
Direct: +1 (617) 674-4143
Toll Free: +1 (855) 711-1555
Fax: +1 (855) 550-5975
SOURCE Big Market Research